This open-label, multi-center study will evaluate the effect on the quantitative HBsAg reduction of peginterferon alfa-2a [PEGASYS] in patients with HBeAg positive chronic hepatitis B. Patients will receive PEGASYS 180 mcg sc once weekly. After 24 weeks of treatment, rapid responders will receive another 24 weeks of treatment. After 24 weeks of treatment, slow responders will be randomized to another 24 or 72 weeks of PEGASYS monotherapy, or to 72 weeks PEGASYS plus 36 weeks adefovir (10 mg, po once daily, starting from week 29 of PEGASYS treatment). The anticipated time on study drug is >2 years.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01086085

Locations

China

Beijing, China, 100044

Beijing, China, 100034

Beijing, China, 100011

Beijing, China, 100050

Changchun, China, 130021

Guangzhou, China, 510515

Shanghai, China, 200433

Shanghai, China, 200040

Shanghai, China, 200025

Wuhan, China, 430030

Xi'an, China, 710038

Sponsors and Collaborators

Hoffmann-La Roche

Major Science and Technology Special Project of China Eleventh Five-year